Drug Profile
FX 003
Alternative Names: FX003Latest Information Update: 04 Mar 2022
Price :
$50
*
At a glance
- Originator Unknown
- Developer Flexion Therapeutics
- Class Anti-inflammatories
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ulcerative colitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Ulcerative-colitis in USA
- 05 Feb 2010 Phase-I clinical trials in Ulcerative colitis in USA (unspecified route)